I. AMENDMENTS

A. In the Claims

Upon entry of the present amendment, the status of the claims will be as follows:

22. (Original) A method for generating a chimeric Candida therapeutic organism from a pathogenic organism that possesses in the wild-type an ~~integrin-like~~ INT1 protein with an I domain, said method comprising:

replacing the I domain in the ~~integrin-like~~ INT1 protein of the pathogenic organism with an antibody fragment that binds to a disease-associated antigen on a diseased cell;

wherein the wild-type pathogenic organism undergoes virulent transformation by binding of the I domain of the surface ~~integrin-like~~ INT1 protein to a cell, and wherein the chimeric Candida therapeutic organism undergoes virulent transformation by binding of the antibody fragment to the disease-associated antigen on the cell.

23. (currently amended) The method of claim 22, wherein the pathogenic organism is *C. albicans* and wherein the method further comprises disabling the wild-type ~~CAFTR~~ high-affinity iron transporter gene in the *C. albicans*, and

introducing a DNA construct comprising a wild-type ~~CAFTR~~ high-affinity iron transporter gene under the control of a EFG1p response element,

wherein binding of the antibody fragment to the disease-associated antigen triggers expression of the CAFTR gene in the DNA construct and filamentous transformation in the chimeric pathogenic *C. albicans*.

24. (original) The method of claim 23, wherein the antibody fragment is a single chain antibody.

25. (original) The method of claim 23, wherein the antibody fragment binds to an antigen on a tumor cell.

26. (original) The method of claim 25, wherein the disease-associated antigen is contained in an abnormal surface protein of the tumor cell.